Engineered immune cells take on lupus in tiny trial
Disease control
Ongoing
This Phase 2 trial is testing a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE). Descartes-08 uses a patient's own immune cells, modified to target a protein called BCMA, to try to control the disease. Only 6 participants with active lupus des…
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC